Menlo Park, CA, United States of America

Oliver Claude Venn

This inventor holds 13 USPTO granted patents and 45 published patent applications, plus 1 CIPO patent and 5 EPO patents. Top assignee: Grail, Inc.. Active years: 2022-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Oliver Claude Venn. Retrieved from https://idiyas.com/inventor/oliver-claude-venn

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 (Patent Applications = 45)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 26)

EPO Patents = 5 (Patent Applications = 41)

Average Co-Inventor Count = 5.4

ph-index = 3

Forward Citations = 20(Granted Patents)

Location History:

Menlo Park, CA (US) (2022 - 2024)
San Francisco, CA (US) (2023 - 2024)

Company Filing History:

13 out of 66

Grail, Inc.

patents

Years Active: 2022-2026

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12580051 - Identifying methylation patterns that discriminate or indicate a cancer condition (2026-03-17),

2. 12497662 - Systems and methods for tumor fraction estimation from small variants (2025-12-16),

3. 12435375 - Methylation markers and targeted methylation probe panel (2025-10-07),

4. 12410482 - Methylation markers and targeted methylation probe panel (2025-09-09),

5. 12234514 - Source of origin deconvolution based on methylation fragments in cell-free DNA samples (2025-02-25),

6. 12191000 - Systems and methods for classifying patients with respect to multiple cancer classes (2025-01-07),

7. 12024750 - Methylation markers and targeted methylation probe panel (2024-07-02),

8. 11961589 - Models for targeted sequencing (2024-04-16),

9. 11795513 - Methylation markers and targeted methylation probe panel (2023-10-24),

10. 11725251 - Methylation markers and targeted methylation probe panel (2023-08-15),

11. 11685958 - Methylation markers and targeted methylation probe panel (2023-06-27),

12. 11581062 - Systems and methods for classifying patients with respect to multiple cancer classes (2023-02-14),

13. 11410750 - Methylation markers and targeted methylation probe panel (2022-08-09),

Title: Oliver Claude Venn: Innovator in Cancer Detection

Introduction

Oliver Claude Venn is a prominent inventor based in Menlo Park, California. He has made significant contributions to the field of cancer diagnostics, holding a total of 11 patents. His work focuses on innovative methods for detecting cancer-specific methylation patterns, which are crucial for early diagnosis and treatment.

Latest Patents

Among his latest patents is a cancer assay panel designed for targeted detection of cancer-specific methylation patterns. This patent outlines methods for designing, making, and using the cancer assay panel for the diagnosis of cancer. The development of such a panel represents a significant advancement in the field of oncology, providing healthcare professionals with essential tools for early detection.

Career Highlights

Oliver currently works at Grail, Inc., a company dedicated to transforming cancer detection through innovative technology. His role at Grail has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research that aims to improve patient outcomes.

Collaborations

Some of his notable coworkers include Samuel S. Gross and Arash Jamshidi. Their combined expertise fosters a collaborative environment that drives innovation and enhances the development of new diagnostic tools.

Conclusion

Oliver Claude Venn's work in cancer detection exemplifies the impact of innovation in healthcare. His contributions through patents and collaboration with other experts continue to pave the way for advancements in cancer diagnostics.

Profile summary based on public USPTO records.